Thymidylate synthase expression and therapeutic effect analysis of pemetrexed in advanced lung adenocarcinoma.
- Author:
Zhi-kuan WANG
1
;
Yi HU
;
Hong ZHAO
;
Chen FU
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; enzymology; Antineoplastic Agents; therapeutic use; Female; Folic Acid Antagonists; therapeutic use; Glutamates; therapeutic use; Guanine; analogs & derivatives; therapeutic use; Humans; Lung Neoplasms; drug therapy; enzymology; Male; Middle Aged; Pemetrexed; Retrospective Studies; Thymidylate Synthase; metabolism
- From: Journal of Southern Medical University 2010;30(5):978-980
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of thymidylate synthase (TS) in patients with advanced lung adenocarcinoma and its relation with the therapeutic effect of pemetrexed.
METHODSThe clinicopathological data of 38 patients with stage IIIIB/IV lung adenocarcinoma receiving pemetrexed treatment were retrospectively analyzed. The tumor samples of the patients were collected for detecting TS expression using RT-PCR, and the therapeutic effect of the treatment was analyzed.
RESULTSTS positivity was found in 26.32 (10/38) of the patients. TS positivity was not correlated to gender, TNM stage or PS score. The total response rate of pemetrexed treatment (CR+PR) was 34.21 (13/38) in these patients, and the rate was 39.29% (11/28) in TS-negative patients, as compared to 20.00% (2/10) in the positive patients (P=0.087). Patients with low TS expression had significantly higher control rate by pemetrexed treatment than those with TS overexpression [89.29% (25/28) vs 40.00% (4/10), P=0.002].
CONCLUSIONTS expression may serve as a potential indicator of chemosensitivity to pemetrexed in patients with advanced lung adenocarcinoma.
